Yasuhiro Nakamura

Yasuhiro Nakamura

Auto-generated profile, based on publicly available information

Yasuhiro Nakamura

Department of Skin Oncology/Dermatology Saitama Medical University International Medical Center Saitama Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2016 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YNYasuhiro Nakamura
Yasuhiro Nakamura
RTRyota Tanaka
Ryota Tanaka
YAYuri Asami
Yuri Asami
YTYukiko Teramoto
Yukiko Teramoto
TITaichi Imamura
Taichi Imamura
AYAkifumi Yamamoto
Akifumi Yamamoto

1 September 2020 in Annals of Oncology
Verified
Journal Article
Closed access
YNY. Nakamura
Y. Nakamura
KNK. Namikawa
K. Namikawa
KYK. Yoshino
K. Yoshino
SYS. Yoshikawa
S. Yoshikawa
HUH. Uchi
H. Uchi
NYN. Yamazaki
N. Yamazaki

25 November 2021 in ESMO Open
Verified
Journal Article
Open access
YNY. Nakamura
Y. Nakamura
KNK. Namikawa
K. Namikawa
SYS. Yoshikawa
S. Yoshikawa
YKY. Kiniwa
Y. Kiniwa
TMT. Maekawa
T. Maekawa
NYN. Yamazaki
N. Yamazaki
Anti-programmed cell death protein 1 (PD-1) antibody monotherapy (PD1) has led to favorable responses in advanced non-acral cutaneous melanoma among Caucasian populations; however, recent studies suggest that this therapy has limited efficacy in mucosal melanoma (MCM). Thus, advanced MCM patients are candidates for PD1 plus anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) combination therapy (PD1 + CTLA4). Data on the efficacy of immunotherapy in MCM, however, are limited. We aimed to compare the efficacies of PD1 and PD1 + CTLA4 in Japanese advanced MCM patients. We retrospectively assessed advanced MCM patients treated with PD1 or PD1 + CTLA4 at 24 Japanese institutions. Patient baseline characteristics, clinical responses (RECIST), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan–Meier analysis, and toxicity was assessed to estimate the efficacy and safety of PD1 and PD1 + CTLA4. Altogether, 329 patients with advanced MCM were included in this study. PD1 and PD1 + CTLA4 were used in 263 and 66 patients, respectively. Baseline characteristics were similar between both treatment groups, except for age (median age 71 versus 65 years; P < 0.001). No significant differences were observed between the PD1 and PD1 + CTLA4 groups with respect to objective response rate (26% versus 29%; P = 0.26) or PFS and OS (median PFS 5.9 months versus 6.8 months; P = 0.55, median OS 20.4 months versus 20.1 months; P = 0.55). Cox multivariate survival analysis revealed that PD1 + CTLA4 did not prolong PFS and OS (PFS: hazard ratio 0.83, 95% confidence interval 0.58-1.19, P = 0.30; OS: HR 0.89, 95% confidence interval 0.57-1.38, P = 0.59). The rate of ≥grade 3 immune-related adverse events was higher in the PD1 + CTLA4 group than in the PD1 group (53% versus 17%; P < 0.001). First-line PD1 + CTLA4 demonstrated comparable clinical efficacy to PD1 in Japanese MCM patients, but with a higher rate of immune-related adverse events.

1 October 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
YNYasuhiro Nakamura
Yasuhiro Nakamura
KNKenjiro Namikawa
Kenjiro Namikawa
YKYukiko Kiniwa
Yukiko Kiniwa
HKHiroshi Kato
Hiroshi Kato
OYOsamu Yamasaki
Osamu Yamasaki
NYNaoya Yamazaki
Naoya Yamazaki

28 November 2019 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YNYasuhiro Nakamura
Yasuhiro Nakamura
JAJun Asai
Jun Asai
HIHiroshi Igaki
Hiroshi Igaki
TITakashi Inozume
Takashi Inozume
KNKenjiro Namikawa
Kenjiro Namikawa
MSMakoto Sugaya
Makoto Sugaya

18 May 2015 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YNYasuhiro Nakamura
Yasuhiro Nakamura
KOKuniaki Ohara
Kuniaki Ohara
AKAkiko Kishi
Akiko Kishi
YTYukiko Teramoto
Yukiko Teramoto
SSSayuri Sato
Sayuri Sato
AYAkifumi Yamamoto
Akifumi Yamamoto